Medical Technology

Current search: " boston blog main "

@xconomy.com 1 month ago

Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin

@xconomy.com 1 month ago

FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats

@xconomy.com 1 month ago

Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More

@xconomy.com 1 month ago

Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More

@xconomy.com 1 month ago

Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More

@xconomy.com 1 month ago

Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs

@xconomy.com 2 months ago

Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More

@xconomy.com 2 months ago

Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D

@xconomy.com 2 months ago

Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue

@xconomy.com 2 months ago

FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures

@xconomy.com 2 months ago

Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More

@xconomy.com 2 months ago

Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally

@xconomy.com 3 months ago

Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases

@xconomy.com 3 months ago

AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact

@xconomy.com 4 months ago

Two Days, Six IPOs, and $1B Raised for Biotech Research & More

@xconomy.com 4 months ago

Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact

@xconomy.com 4 months ago

Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later

@xconomy.com 5 months ago

CereVasc Lands $44M for New Medical Device to Drain “Water on the Brain”

@xconomy.com 6 months ago

HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic

@xconomy.com 6 months ago

Join us this Wednesday for Xcelerating Life Sciences: Biopharma’s Future in Digital Health

@xconomy.com 6 months ago

Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health

@xconomy.com 6 months ago

Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health

@xconomy.com 6 months ago

Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs

@xconomy.com 6 months ago

Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health

@xconomy.com 6 months ago

Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses

@xconomy.com 6 months ago

Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health

@xconomy.com 6 months ago

Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health

@xconomy.com 7 months ago

Early Bird Sale Ends Today for Xcelerating Life Sciences Boston: Biopharma’s Future in Digital Health

@xconomy.com 7 months ago

Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More

@xconomy.com 7 months ago

VenBio Partners Bags $394M to Back More Medicine-Making Biotechs

@xconomy.com 8 months ago

Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More

@xconomy.com 9 months ago

EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device

@xconomy.com 9 months ago

Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks

@xconomy.com 9 months ago

Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer

@xconomy.com 9 months ago

Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy

@xconomy.com 9 months ago

Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More

@xconomy.com 9 months ago

With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14